6.3.2. residual tumour resection. 6.3.2.1. seminoma residual mass seminoma initially monitored imaging tumour markers [198-200]. fdg-pet high npv, patients residual masses > 3 cm largest diameter, considered order provide information disease viability [201-203]. performed least two months completion chemotherapy, inflammation desmoplastic reaction induced chemotherapy may result false positive result . npv active disease > 90% reassuring . contrast ppv ranges 23-69% thus caution advised initiating active therapy driven positive findings fdg-pet-ct . post-chemotherapy mass remains positive reclassification fdg-pet volume increase, repeat fdg-pet performed six weeks later. recent publication shows low ppv vital tumours residual lesions (generally > 3 cm) chemotherapy metastatic seminoma (11-38% depending sub-group). therefore, caution recommended fdg-pet single parameter drive clinical decisions persistent mass . patients progressive disease radiological criteria (i.e., growing mass enhances cect fdg-pet avid), salvage therapy indicated [206-208]. patients persistently high and/or progressing β-hcg elevation first-line chemotherapy proceed salvage chemotherapy. progressing patients without β-hcg progression undergo histological verification (e.g., percutaneous surgical biopsy) salvage chemotherapy given. rplnd indicated, performed referral centres, residual seminoma masses may extremely difficult remove due intense fibrosis . 6.3.2.2. non-seminoma following first-line bep reported 7% residual masses contain active cancer, 33% post-pubertal teratoma, 40% necrotic-fibrotic tissue . remainder comprise rarer entities including malignant transformation teratoma. restaging patients following chemotherapy fdg-pet indicated . complete radiological remission, rplnd indicated . usual timing restaging three four weeks beginning last cycle. diagnostic risk calculator accurately predict histology residual masses. thus, resection mandatory patients residual mass > 1 cm transaxial long axis cross-sectional cect imaging novel predictive models externally validated [212-215]. surgery indicated performed within six eight weeks last chemotherapy cycle. role surgery residual retroperitoneal lesions < 1 cm uncertain. difficult distinguish true residual node 10 mm complete remission, many authors consider situations equivalent. residuals containing cancer teratoma possible, vast majority patients fibro-necrotic tissue . whilst post-chemotherapy rplnd residuals < 10 mm transaxial long axis complete remission option , alternative option close surveillance recurrence risk 6-9% depending follow-up duration [209-211,218]. series longest follow-up 15.5 years, twelve (9%) 141 patients relapsed despite complete response following primary treatment . eight twelve relapsing patients cured subsequent treatment. cases discussed individual basis considering orientation expectations patient. residual masses salvage chemotherapy hdct first subsequent salvage situations greater risk active disease . surgery therefore indicated even residual masses < 1 cm . resection indicated, bilateral nerve sparing rplnd standard option. ipsilateral template resection avoids contralateral nerve dissection may considered residuals diameter < 5 cm , well unilateral lymph node metastases pre- post-chemotherapy ct scans, left-sided tumours require para-aortic resection whereas right-side tumours need paracaval inter-aortocaval resection iliac arteries . mapping studies indicate potential risk contralateral disease approach low around 1-3% . mere resection residual tumour (so called lumpectomy) performed . laparoscopic robotic rplnd may yield comparable outcomes open procedures selected cases, low-volume residual disease undertaken highly experienced surgeons. considered specialist tc centres expertise open rplnd minimally invasive surgery ensure appropriate case selection. setting, 30% post-chemotherapy rplnd reported via laparoscopic approach [225-227]. experience robot-assisted laparoscopic rplnd, specifically long-term outcomes remains limited . atypical recurrences reported occur often approach .